SUMICHEM Q4 FY26 earnings call.
A source-linked concall view: reported numbers, management language, guidance, commitments and risks that should carry forward.
ConCallIQ research layer
Signal, with the source still visible.
Use the controls below to narrow the view, then follow the evidence into the next layer of context.
Revenue
₹684 Cr
verified against source
Revenue YoY
3%
reported change
EBITDA
₹671 Cr
latest reported figure
Source
screener in
record provenance
Actual signal trajectory
Where this quarter sits.
Quarter read
What the record says.
Sumitomo Chemical India delivered record profitability in FY26 despite a challenging operating environment marked by prolonged monsoon disruptions, bio-stimulant regulatory constraints, and geopolitical uncertainties. Revenue grew 3% to ₹3,238 crore while PAT reached a record ₹543 crore, up 7% YoY with EBITDA margin expanding 64 basis points to 20.7%. The management attributed outperformance to structural improvements in business mix, higher branded formulation share (81% of domestic revenue), and disciplined pricing. Q4 showed more modest growth with 1% revenue increase to ₹684 crore, though margin expansion remained strong. Looking ahead to FY27, management struck a cautiously optimistic tone—recent price increases (three since mid-March) aim to offset input cost inflation, but below-normal monsoon forecasts (92% LPA with 82% El Niño probability) and geopolitical headwinds represent key risks to the outlook. The leadership transition planned for September 2026 was characterized as well-prepared with strong succession depth.
Colored figures show movement against the previous available record.
Guidance to track
- Current annual run-rate is approximately ₹100-150 crore depending on market conditions. Growth expected from next financial year onwards as capex projects are implemented.
- First project of ₹150 crore announced at Dahanu site, expected to be commercialized in approximately 2 years. Additional projects in advanced feasibility stages with similar quantum expected to be announced periodically over the next few years.
- New bio-stimulant from parent company's biorational portfolio received registration; to be commercialized in the upcoming kharif season.
- One additional product awaiting regulatory approval; upon receipt, the company intends to launch within the current financial year.
Risks flagged
- IMD forecasts southwest monsoon at 92% of long-period average (below normal), with 82% probability of El Niño emergence during May-July. This could significantly impact rabi season recovery and full-year demand.
- Depreciating rupee, escalating costs across raw materials, packaging materials, solvents, and transportation driven by geopolitical developments. Management has implemented three price increases but sustainability of pass-through remains uncertain.
- Global container availability constrained towards end of Q4 and into early FY27, with shipment delays experienced including to Africa. Management characterizes this as episodic and manageable rather than structural.
- Net working capital days increased to 103 from 89 days year-over-year due to deliberate inventory buildup ahead of kharif. This represents tied-up capital in a rising cost environment.
Key quotes
- This was one of the most challenging years in the Indian agrochemical industry that I have personally seen... And yet in that environment, Sumitomo Chemical India delivered its highest ever profitability.
- The headline revenue growth of 3% for FY26 understates the underlying momentum of the core crop production business... the domestic franchise demonstrating genuine resilience.
- We are not taking a one-shot decision and trying to recover everything. We are taking a calculated decision based on the product, based on the brand, based on the popularity of the brand.
Research modules